Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LM-108 + Sintilimab in Advanced NSCLC
NCT06479759Phase 2Recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Jan 2024
- Primary completion
- Jun 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of LM-108 in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pulmonary Hospital. Started Jan 2024; status: recruiting.
02
Drugs
LM-108
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06479759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06479759.